2/1
06:31 am
rdy
Dr. Reddy's Laboratories (NYSE:RDY) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
Low
Report
Dr. Reddy's Laboratories (NYSE:RDY) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
1/30
08:51 am
rdy
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's [Seeking Alpha]
Low
Report
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's [Seeking Alpha]
1/25
08:31 pm
rdy
Dr Reddy's Laboratories Ltd (RDY) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
Low
Report
Dr Reddy's Laboratories Ltd (RDY) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
1/21
11:41 pm
rdy
Dr. Reddy's GAAP EPS of ?14.52, revenue of ?87.27B [Seeking Alpha]
Low
Report
Dr. Reddy's GAAP EPS of ?14.52, revenue of ?87.27B [Seeking Alpha]
1/21
04:27 pm
rdy
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript [Seeking Alpha]
Low
Report
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript [Seeking Alpha]
1/21
12:41 pm
rdy
Dr. Reddy's Laboratories Q3 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Dr. Reddy's Laboratories Q3 Earnings Call Highlights [Yahoo! Finance]
1/17
04:31 pm
rdy
Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at
Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
Low
Report
Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at
Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
1/14
08:49 am
rdy
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
Low
Report
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
12/2
08:00 am
rdy
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
Low
Report
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
11/18
09:51 am
rdy
ValGenesis Wraps Up Global ValConnect Innovation Day Series with Hyderabad Event [Yahoo! Finance]
Low
Report
ValGenesis Wraps Up Global ValConnect Innovation Day Series with Hyderabad Event [Yahoo! Finance]